Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.64 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.64 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.64 |
| ▸ | MAOA | P21397 | 1/20 | 0.64 |
| ▸ | CA1 | P00915 | 3/20 | 0.56 |
| ▸ | CA2 | P00918 | 3/20 | 0.56 |
| ▸ | CA12 | O43570 | 2/20 | 0.56 |
| ▸ | CA7 | P43166 | 2/20 | 0.56 |
| ▸ | CA9 | Q16790 | 2/20 | 0.56 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.56 |
| ▸ | ESR1 | P03372 | 1/20 | 0.56 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.53 |
| ▸ | STS | P08842 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 5/20 | 0.49 |
| ▸ | RAB9A | P51151 | 3/20 | 0.49 |
| ▸ | NPC1 | O15118 | 2/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 4/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5831347 | 0.93 | LMNA (0.55) | LMNACYP1A2CYP3A4MAOACA1 | |
| SCHEMBL12771413 | 0.86 | LMNA (0.62) | LMNACYP1A2CYP3A4MAOACA1 | |
| SCHEMBL2406478 | 0.84 | LMNA (0.60) | LMNACYP1A2CYP3A4MAOACA1 | |
| SCHEMBL8879486 | 0.84 | LMNA (0.56) | LMNACYP1A2CYP3A4MAOACA1 | |
| SCHEMBL10661402 | 0.83 | LOXL2 (0.62) | CA1CA2CA12CA7CA9 | |
| SCHEMBL27925916 | 0.82 | LMNA (0.57) | LMNACYP1A2CYP3A4MAOACA1 | |
| SCHEMBL27667917 | 0.82 | CA1 (0.79) | LMNACYP1A2CYP3A4MAOACA1 | |
| SCHEMBL7670282 | 0.81 | LMNA (0.53) | LMNACYP1A2CYP3A4MAOACA1 | |
| SCHEMBL28245978 | 0.81 | LMNA (0.56) | LMNACYP1A2CYP3A4MAOACA1 | |
| SCHEMBL4862590 | 0.80 | MAPT (0.51) | LMNASMN1; SMN2RAB9ANPC1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3022173-B1 | COMPOUNDS FOR THE TREATMENT AND/OR PREVENTION OF PARASITIC DISEASES AND METHOD OF PRODUCTION THEREOF | INSTITUT DE RECH POUR LE DEVELOPPEMENT I R D (FR) | 2019-02-20 | — | — | EP | disclosed |
| US-20190040004-A1 | NEW COMPOUNDS FOR THE TREATMENT AND/OR PREVENTION OF PARASITIC DISEASES AND METHOD OF PRODUCTION OF THEREOF | UNIVERSITE DE MONTPELLIER (FR) | 2019-02-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190040004-A1 | NEW COMPOUNDS FOR THE TREATMENT AND/OR PREVENTION OF PARASITIC DISEASES AND METHOD OF PRODUCTION OF THEREOF | PIGO, TTPA, TST | LMNA 1706/4885CYP1A2 497/4885CYP3A4 778/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.